Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium hyaluronate 0.18%
- Development stage
- Unknown
- Lead developer
- TRB Chemedica
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Sodium hyaluronate 0.18% is a hypotonic ophthalmic solution used primarily for the treatment of dry eye disease (keratoconjunctivitis sicca). It functions as a lubricant that moistens the eyes and provides temporary relief from burning and discomfort. The 0.18% concentration is specifically formulated as a hypotonic solution, which has been shown to be more effective in improving tear film stability and ocular surface integrity compared to isotonic 0.1% sodium hyaluronate eye drops in patients with mild dry eye disease.
- Other names
- hyaluronate sodium 0.18%hyaluronic acid 0.18%
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on sodium hyaluronate 0.18%.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium hyaluronate 0.18%.